GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Can Cultured Cell Therapy Be Completed in One Day?

Short answer: Not if you mean collecting your cells, growing them in a lab, and giving the cultured cells back on the same day. A treatment visit may take place in one day if the cells were grown earlier and meet the protocol’s release requirements. That is not a one-day collection-to-treatment process. Ask whether the advertised day covers collection, administration, or the whole process.

What “one day” means

Cultured means the lab takes cells from a sample and grows more of them for a planned dose. Uncultured stromal vascular fraction (SVF) from fat and bone marrow aspirate concentrate (BMAC) do not undergo that expansion step. They are different preparations, not faster versions of the same cultured product. If you have only one day on site, identify which arrangement the clinic means.

Can Cultured Cell Therapy Be Completed in One Day?
What “one day” refers to Cultured from your fresh sample? Ask the clinic
Collection and injection on the same day No — there is no culturing step Which product is it, and what is its own evidence?
One visit inside a longer course Yes, but grown between visits When was my sample grown, and what happens between visits?
Treatment from a stored, earlier batch Made earlier, not from your same-day sample Whose cells are these, and what are the release results?
A full autologous cultured course Yes — and it cannot fit in one day What is the realistic collection-to-treatment interval?

Why cultured treatment needs more days

In a cultured-cell protocol, collection supplies the starting material; expansion happens before administration. The relevant interval is from collection to a batch that meets the protocol’s requirements, not just the time spent at the clinic. There is no single verified turnaround time for all products in the evidence reviewed here. Ask the clinic for its protocol-specific interval and what happens if the batch cannot be released.

The U.S. MILES trial illustrates why the testing schedule matters. It enrolled 480 adults aged 40–70 with Kellgren–Lawrence grade 2–4 knee osteoarthritis. The single-blind phase 2/3 trial compared BMAC, autologous SVF, and allogeneic umbilical-cord-tissue mesenchymal stromal cells with corticosteroid injections into the knee. Pre-injection checks included cell count, viability, and endotoxin. One BMAC preparation and four SVF preparations failed endotoxin testing and were not injected. A 14-day sterility test produced results after administration in this trial.PMC10719084

That does not establish a universal 14-day wait before treatment, nor a culture duration for your product. The rejected BMAC and SVF preparations were not freshly culture-expanded products. Ask which results must be available before administration and whether any tests finish afterward.

Treatment time is not follow-up time

Follow-up measures outcomes after treatment. It does not tell you how long manufacturing took or require you to stay at the clinic for months.

A Japanese retrospective study reviewed 80 patients (128 knees) with grade 2–4 knee osteoarthritis after standard treatment had failed. Forty-two patients (59 knees) received about 12.75 million cultured adipose-derived cells; 38 patients (69 knees) received 5 mL of uncultured SVF. At six months, mean pain-score reductions were 55% and 44%, respectively. Responder rates were 61% and 55% (P=.25), a difference that was not statistically significant. This non-randomized comparison with six-month follow-up cannot establish that either preparation is generally better.31373830

The MILES primary analysis included 440 patients. At one year, it found no significant superiority in pain outcomes among the cell groups or over corticosteroid, and no significant MRI improvement. No study-related serious adverse events were reported. The trial ran under IND #18414, a research authorization rather than product approval.PMC10719084 These knee-injection findings do not establish benefits for IV treatment, other diseases, or anti-aging. Neither study makes appointment length a measure of effectiveness.

What rushing into one day risks

A short visit does not establish safety. The contamination incident below is a reason to ask about product handling and follow-up, not evidence that a one-day visit caused infection.

In a 2018 U.S. investigation, 12 patients in three states developed infections linked to unapproved cord-blood-derived products. Bacteria were found in unopened vials, suggesting contamination before distribution. All 12 patients were hospitalized; no deaths were reported.Mm6750a5.htm This incident involved one product chain, not all cell therapies.

Collection brings its own risks. The harvest site can bleed, hurt, or become infected. Shots carry risks that change with the injection site. Handling, storage, and thawing add further risks. A short trip makes follow-up harder after you fly home. Japan’s rules draw a clear line. The Act on the Safety of Regenerative Medicine took effect on November 25, 2014.13_en.pdf It requires clinics, including private clinics, to file provision plans.13_en.pdf Those filings cover how clinics provide care. They do not prove the treatment works. They are separate from full product approval.13_en.pdf In the United States, the cord-blood approvals cited in that investigation covered blood and immune reconstitution, not joint injections for pain or aging.Mm6750a5.htm FDA’s current approved cellular and gene therapy list should be checked by exact product and indication.Approved cellular and gene therapy products

What to ask with limited days

For a practical planning example, suppose you can attend only on Friday. If Friday is your first collection visit, do not assume a cultured-cell dose from that sample will also be ready that afternoon. If a batch was prepared earlier, ask when it was made, whose cells it contains, and whether it meets the release requirements. This is a planning example, not a patient case or an account of clinical experience.

Before booking travel, request written answers to these questions:

  • Did my cells come from my own fresh sample and grow in the lab, or are they uncultured, or from an older stored batch?
  • What is the likely wait between collection and treatment in my case, and what could stretch it?
  • Which release tests will you run on my batch, and will I see all results before the shot?
  • If my sample grows poorly or my batch fails, will you delay, repeat, or cancel the treatment — and who pays?
  • What evidence backs this exact product, dose, and route for my condition, how long did follow-up run, which side effects appeared — and who looks after me if problems start after I return home?

Planning travel around a cultured-cell course? Bring your diagnosis summary and the exact protocol, and ask for written answers before you book.

Contact the support team

Bottom line

A one-day administration visit may be possible for cells prepared earlier; collection, culture expansion, and administration from a fresh sample are not the same-day process. Ask for a written collection date, expected batch-release date, treatment date, and follow-up plan. Neither a short schedule nor a longer culture period proves that a treatment is effective or suitable for you.